Reassessing the Role of the Active TGF-β 1 as a Biomarker in Systemic Sclerosis: Association of Serum Levels with Clinical Manifestations

Disease Markers

Volumn 2016, Issue , 2016, Pages

  Dantas, Andreá Tavares ^a,b   Goncąlves, Sayonara Maria Calado ^b   Almeida, Anderson Rodrigues De ^b   Goncąlves, Rafaela Silva Guimarães ^a,b   Sampaio, Maria Clara Pinheiro Duarte ^b   Vilar, Kamila De Melo ^b   Pereira, Michelly Cristiny ^b   Rêgo, Moacyr Jesus Barreto De Melo ^b   Pitta, Ivan Da Rocha ^a   Marques, Claudia Diniz Lopes ^a   Duarte, Angela Luzia Branco Pinto ^a   Pitta, Maira Galdino Da Rocha ^b  

^a FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

^b Laboratório de Imunomodulação e Novas Abordagens Terapêuticas Núcleo de Pesquisa Em Inovação Terapêutica Suely Galdino   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; MESSENGER RNA; TRANSFORMING GROWTH FACTOR BETA1; TGFB1 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CELL CULTURE; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; FINGER ULCER; HUMAN; HUMAN TISSUE; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SCORING SYSTEM; SKIN BIOPSY; SYSTEMIC SCLEROSIS; BIOPSY; BLOOD; CASE CONTROL STUDY; COMPARATIVE STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; GENETICS; METABOLISM; MIDDLE AGED; MONONUCLEAR CELL; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; SCLERODERMA, SYSTEMIC; SKIN; YOUNG ADULT;

ADULT; AGED; BIOMARKERS; BIOPSY; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; SCLERODERMA, SYSTEMIC; SKIN; TRANSFORMING GROWTH FACTOR BETA1; YOUNG ADULT;

EID: 84999633554     PISSN: 02780240     EISSN: 18758630     Source Type: Journal    
DOI: 10.1155/2016/6064830     Document Type: Article

References (32)

1. J. Varga and B. Pasche, "Transforming growth factor beta as a therapeutic target in systemic sclerosis, " Nature Reviews Rheumatology, vol. 5, no. 4, pp. 200-206, 2009.
2. R. Lafyatis, "Transforming growth factor-at the centre of systemic sclerosis, " Nature Reviews Rheumatology, vol. 10, no. 12, pp. 706-719, 2014.
3. Y. S. Gu, J. Kong, G. S. Cheema, C. L. Keen, G. Wick, M. E. Gershwin, "The immunobiology of systemic sclerosis, " Seminars in Arthritis and Rheumatism, vol. 38, no. 2, pp. 132-160, 2008.
4. J. Gordon, U. Udeh, K. Doobay et al., "Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 24-month open label, extension phase, singlecentre trial, " Clinical and Experimental Rheumatology, vol. 32, supplement 86, no. 6, pp. S189-S193, 2014.
5. P. Fraticelli, B. Gabrielli, G. Pomponio et al., "Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study, " Arthritis Research & Therapy, vol. 16, no. 4, article R144, 2014.
6. S. Prey, K. Ezzedine, A. Doussau et al., "Imatinib mesylate in scleroderma-associated diffuse skin fibrosis: a phase II multicentre randomized double-blinded controlled trial, " The British Journal of Dermatology, vol. 167, no. 5, pp. 1138-1144, 2012.
7. N. Snowden, B. Coupes, A. Herrick, K. Illingworth, M. I. V. Jayson, P. E. C. Brenchley, "Plasma TGF beta in systemic sclerosis: a cross-sectional study, " Annals of the Rheumatic Diseases, vol. 53, no. 11, pp. 763-767, 1994.
8. S. Sato, M. Hasegawa, K. Takehara, "Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis, " Journal of Dermatological Science, vol. 27, no. 2, pp. 140-146, 2001.
9. E. Scala, S. Pallotta, A. Frezzolini et al., "Cytokine and chemokine levels in systemic sclerosis: relationship with cutaneous and internal organ involvement, "Clinical and Experimental Immunology, vol. 138, no. 3, pp. 540-546, 2004.
10. M. Dziadzio, R. E. Smith, D. J. Abraham, C. M. Black, C. P. Denton, "Circulating levels of active transforming growth factor 1 are reduced in diffuse cutaneous systemic sclerosis and correlate inversely with the modified Rodnan skin score, " Rheumatology, vol. 44, no. 12, pp. 1518-1524, 2005.
11. T. Matsushita, M. Hasegawa, Y. Hamaguchi, K. Takehara, S. Sato, "Longitudinal analysis of serum cytokine concentrations in systemic sclerosis: association of interleukin 12 elevationwith spontaneous regression of skin sclerosis, " Journal of Rheumatology, vol. 33, no. 2, pp. 275-284, 2006.
12. S. Vettori, G. Cuomo, M. Iudici et al., "Early systemic sclerosis: serum profiling of factors involved in endothelial, T-cell, fibroblast interplay is marked by elevated interleukin-33 levels, " Journal of Clinical Immunology, vol. 34, no. 6, pp. 663-668, 2014.
13. Preliminary Criteria for the Classification of Systemic Sclerosis (scleroderma), "Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee, " Arthritis & Rheumatology, vol. 23, no. 5, pp. 581-590, 1980.
14. E. C. LeRoy, C. Black, R. Fleischmajer et al., "Scleroderma (systemic sclerosis): classification, subsets and pathogenesis, " Journal of Rheumatology, vol. 15, no. 2, pp. 202-205, 1988.
15. A. T. Dantas, S. M. C. Goncąlves, M. C. Pereira et al., "Interferons and systemic sclerosis: correlation between interferon gamma and interferon-lambda 1 (IL-29), " Autoimmunity, vol. 48, no. 7, pp. 429-433, 2015.
16. A. T. Dantas, M. C. Pereira, M. J. B. de Melo Rego et al., "The role of PPAR gamma in systemic sclerosis, " PPAR Research, vol. 2015, Article ID124624, 12 pages, 2015.
17. P. Clements, P. Lachenbruch, J. Siebold et al., "Inter and intraobserver variability of total skin thickness score (Modified Rodnan TSS) in systemic sclerosis, " Journal of Rheumatology, vol. 22, no. 7, pp. 1281-1285, 1995.
18. L. D. Carbone, K. J. Warrington, K. D. Barrow et al., "Pamidronate infusion in patients with systemic sclerosis results in changes in blood mononuclear cell cytokine profiles, " Clinical and Experimental Immunology, vol. 146, no. 3, pp. 371-380, 2006.
19. J. Pope, K. M. Walker, F. de Leon, L. Vanderhoek, S. Seney, K. L. Summers, "Correlations between changes in cytokines and clinical outcomes for early phase (proof of concept) trials in active diffuse systemic sclerosis using data from an imatinib study, " Rheumatology, vol. 53, no. 10, pp. 1830-1834, 2014.
20. I. E. Fernandez and O. Eickelberg, "The impact of TGF-on lung fibrosis: from targeting to biomarkers, " Proceedings of the American Thoracic Society, vol. 9, no. 3, pp. 111-116, 2012.
21. S.-J. Yong, A. Adlakha, A. H. Limper, "Circulating transforming growth factor-1: a potential marker of disease activity during idiopathic pulmonary fibrosis, " Chest, vol. 120, no. 1, supplement, pp. 68s-70s, 2001.
22. M. Molina-Molina, S. Lario, P. Luburich, J. Raḿrez, M. T. Carrión, A. Xaubet, "Quantifying plasma levels of transforming growth factor 1 in idiopathic pulmonary fibrosis, " Archivos de Bronconeumologia, vol. 42, no. 8, pp. 380-383, 2006.
23. A. Ludwicka, T. Ohba, M. Trojanowska et al., "Elevated levels of platelet derived growth factor and transforming growth factor-beta 1 in bronchoalveolar lavage fluid from patients with scleroderma, " Journal of Rheumatology, vol. 22, no. 10, pp. 1876-1883, 1995.
24. K. Schmidt, L. Martinez-Gamboa, S. Meier et al., "Bronchoalveoloar lavage fluid cytokines and chemokines as markers and predictors for the outcome of interstitial lung disease in systemic sclerosis patients, " Arthritis Research & Therapy, vol. 11, no. 4, article R111, 2009.
25. F. Meloni, R. Caporali, A. Marone Bianco et al., "BAL cytokine profile in different interstitial lung diseases: a focus on systemic sclerosis, " Sarcoidosis, Vasculitis and Diffuse Lung Diseases, vol. 21, no. 2, pp. 111-118, 2004.
26. Y. Hamaguchi, "Autoantibody profiles in systemic sclerosis: predictive value for clinical evaluation and prognosis, " The Journal of Dermatology, vol. 37, no. 1, pp. 42-53, 2010.
27. M. R. Brown, J. Vaughan, L. L. Jimenez, W. Vale, A. Baird, "Transforming growth factor-: role in mediating seruminduced endothelin production by vascular endothelial cells, " Endocrinology, vol. 129, no. 5, pp. 2355-2360, 1991.
28. C. Lambers, M. Roth, J. Zhong et al., "The interaction of endothelin-1 and TGF-1 mediates vascular cell remodeling, " PLoS ONE, vol. 8, no. 8, Article ID e73399, 2013.
29. V. Liakouli, P. Cipriani, A. Marrelli, S. Alvaro, P. Ruscitti, R. Giacomelli, "Angiogenic cytokines and growth factors in systemic sclerosis, " Autoimmunity Reviews, vol. 10, no. 10, pp. 590-594, 2011.
30. M. Hasegawa, Y. Asano, H. Endo et al., "Serum chemokine levels as prognostic markers in patients with early systemic sclerosis: a multicenter, prospective, observational study, " Modern Rheumatology, vol. 23, no. 6, pp. 1076-1084, 2013.
31. R. Giacomelli, P. Cipriani, C. Danese et al., "Peripheral blood mononuclear cells of patients with systemic sclerosis produce increased amounts of interleukin 6, but not transforming growth factor 1, " The Journal of Rheumatology, vol. 23, no. 2, pp. 291-296, 1996.
32. M. Hasegawa, S. Sato, K. Takehara, "Augmented production of transforming growth factor-by cultured peripheral blood mononuclear cells from patients with systemic sclerosis, " Archives of Dermatological Research, vol. 296, no. 2, pp. 89-93, 2004.